![](https://investorshub.advfn.com/uicon/522650.png?cb=1464431304)
Wednesday, May 13, 2015 1:08:44 PM
This e-mail from Pfizer just appeared in my inbox. I have previously documented how Pfizer has been working with non-commercial entities, specifically an organization called Rethink Opioids, to re-educate prescribers to think about prescribing an ADF opioid as a "Universal Precaution." The previous e-mails have been from third-parties and have been free of commercial influence. As I predicted, now comes Pfizer with specific details of the agonist-antagonist ADF Embeda.
Nasrat Hakim:
Number two when a company like Pfizer embraces the technology which little Elite has that would tell you that we have as a gold cup, okay. So this is how I look at it, it’s very positive, this is a wonderful thing that little Elite has the same thing that Pfizer had and maybe a little better and second Pfizer is paving the way for us, another giant is going to jump in and want to partner with us down the road in order to compete with Pfizer.
My previous post:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112929084
This is a perfect example of what NH was saying. Completely in the background, Pfizer has started to introduce the idea of prescribing only ADF-opioids. Below is the link to Rethink Opioids. It is a very well-done site, evidence-based medicine with nil commercial influence. Play around on the site and see if you can find the section on agonist/antagonist abuse-deterrence. Not easy to find but its there, and I bet in the near future I'll be hearing more from Pfizer on this issue.
"There are three kinds of lies: lies, damned lies, and statistics."
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM